Your session is about to expire
← Back to Search
11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
Phase 2
Waitlist Available
Led By Don Wilson, MD, FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks
Awards & highlights
No Placebo-Only Group
Summary
The overall sensitivity and specificity of 11C-MET PET/CT is superior to 18F-FDG PET/CT and conventional SPECT-CT for the detection of abnormal parathyroid glands.
Eligible Conditions
- Primary Hyperparathyroidism
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ patient will undergo the scans at baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient will undergo the scans at baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To compare the sensitivity of 11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism
To compare the specificity of11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism
Secondary study objectives
To evaluate the safety profile of 11C-MET PET/CT.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Primary hyperparathyroidismExperimental Treatment3 Interventions
Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,481 Previous Clinical Trials
2,494,866 Total Patients Enrolled
British Columbia Cancer AgencyOTHER
176 Previous Clinical Trials
95,178 Total Patients Enrolled
Don Wilson, MD, FRCPCPrincipal InvestigatorBritish Columbia Cancer Agency
Donald W Anderson, MD, FRCSCPrincipal InvestigatorUniversity of British Columbia; Vancouver General Hospital